Sign in
Taking people in United StatesNo phase

Brain scan method to tell radiation damage from returning brain tumors

Tests a quick MRI technique in people with brain tumors after radiotherapy.

Key facts

Who runs it
Case Comprehensive Cancer Center
Where
Cleveland, United StatesSee the 2 sites
Trial code
Registry title
Development of MRF for Characterization of Brain Tumors After Radiotherapy
Status
Recruiting
People taking part
90 people, planned
Started
14 Oct 2024
Expected to end
Sept 2027
Type of study
Interventional, 6 groups
Treatments tested
  • MRF in conjunction with IVIM MRI without contrast
Record updated
20 October 2026

Who can take part

The trial is looking for adults to have one MRI brain scan. It takes healthy volunteers and people with brain tumors, tumors that came back, or brain damage from radiation (radiation necrosis).

Age
Healthy volunteers: 18 to 60 years. People with brain tumors: 18 years and over.
Sex
All sexes can join.
Disease stage
Patients need a tumor that came back or radiation necrosis after radiation, or an untreated glioma, brain metastases or meningioma that can be removed by surgery. This must be shown by biopsy, scans or a doctor team. ECOG performance status (daily activity level) 0-2. Life expectancy > 6 months. Healthy volunteers must have no brain blood vessel disease and no memory or thinking problems.
Earlier treatment
People with glioma, brain metastases or meningioma cannot have had radiation or surgery for them before. Treatment elsewhere in the body is reviewed case by case.
Main reasons for not taking part
  • Pregnant or breastfeeding women
  • Metal implants, clips, pacemakers or defibrillators that are not safe in MRI
  • Metal pieces in the body such as bullets or shrapnel
  • Severe fear of closed spaces (claustrophobia)
  • Not able to lie still in the scanner for 30 minutes
Show the full registry criteria (33)Hide the full registry criteria

Who can take part

  • Ages 18 - 60
  • No history of cerebrovascular disease
  • No cognitive impairments
  • Able to provide informed consent
  • Biopsy-proven cases of developed recurrent tumor or radiation necrosis, OR
  • a. PET identified with developed recurrent tumor or radiation necrosis. OR
  • b. Highly suspicious case with developed recurrent tumor or radiation necrosis confirmed by tumor board, attending physician or surgeon
  • Age: 18 years and over
  • ECOG performance status 0-2
  • Life expectancy > 6 months
  • Participant with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis
  • Radiology identified with developed primary gliomas tumor or brain metastases, OR
  • a. PET identified with developed gliomas tumor or brain metastases, OR
  • b. Highly suspicious case with developed gliomas tumor or brain metastases confirmed by tumor board
  • Participants must not have received prior radiation or surgical treatment for brain metastases or primary glioma
  • Age: 18 years and over
  • ECOG performance status 0-2
  • Life expectancy > 6 months
  • Participant with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis
  • Radiology identified with resectable meningioma
  • Participants have no prior radiation or surgical treatment for brain lesions
  • Age: 18 years or older
  • ECOG performance status 0-2
  • Life expectancy > 6 months
  • Participants with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis

Who cannot take part

  • Participants who cannot go into the MRI scanner due to metal implants and other medical conditions
  • Known history of severe claustrophobia
  • Participants under the age of 18
  • Pregnant women OR lactating women
  • Participants with ferromagnetic or otherwise non-MRI compatible aneurysm clips
  • The presence of an implanted medical device that is not MRI-compatible, including, but not limited to: pacemaker, defibrillator
  • Participants with contraindications for MRI due to embedded foreign metallic objects such as bullets, shrapnel, metalwork fragments, or other metallic material
  • Participants unable to lay still in the scanner for 30 minutes at a time

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in United States.

  • Cleveland Clinic Taussig Cancer CenterCleveland, United StatesContact: Lan Lu, PhDTaking people
  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer CenterCleveland, United StatesContact: Chaitra A Badve, MDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced quantitative assessment of brain tissues. This method is being applied with IVIM MRI to be able to tell the difference between a brain with radiation necrosis and a brain with tumor recurrence. Participants will consist of individuals who have received radiation therapy in the past and were diagnosed with radiation necrosis, individuals with recurrent tumors, individuals with previously untreated tumors, and healthy individuals who have no brain diseases and have not had radiation treatment to the brain. Participants will undergo an MRI scan at a one-time research study visit; no extra tests or procedures will be required for this research study.

Read full original descriptionShow less

The primary objectives of this study are:

* To demonstrate the clinical feasibility of combining MRF with state-of-the-art parallel imaging techniques to achieve high-resolution quantitative imaging within a reasonable scan time of 5 min for whole brain coverage. * To apply the developed quantitative approach in combination with IVIM MRI for differentiation of tumor recurrence and radiation necrosis. * To investigate the effect of radiation dose on the development of radiation necrosis and tumor recurrence.

The 6 groups in the trial

  • Healthy Volunteer ParticipantsTreatment being tested

    Healthy volunteers will be recruited to evaluate the capability of MRF in conjunction with intravoxel incoherent motion (IVIM) MRI and serve as healthy control data to compare with the participant data.

    Treatment: MRF in conjunction with IVIM MRI without contrast

  • Participants with Radiation NecrosisTreatment being tested

    The MRI scans (MRF and IVIM) will be performed on participants with newly developed necrosis prior to any further therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings

    Treatment: MRF in conjunction with IVIM MRI without contrast

  • Participants with Tumor RecurrenceTreatment being tested

    The MRI scans (MRF and IVIM) will be performed on participants with newly developed recurrent prior to any further therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings

    Treatment: MRF in conjunction with IVIM MRI without contrast

  • Participants with Brain MetastasesTreatment being tested

    The MRI scans (MRF and IVIM) will be performed on participants with newly developed, untreated brain metastases prior to any therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings

    Treatment: MRF in conjunction with IVIM MRI without contrast

  • Participants with Primary GliomasTreatment being tested

    The MRI scans (MRF and IVIM) will be performed on participants with newly developed, untreated primary gliomas prior to any therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings

    Treatment: MRF in conjunction with IVIM MRI without contrast

  • Participants with MeningiomasTreatment being tested

    The MRI scans (MRF and IVIM) will be performed on participants with meningiomas who have not yet undergone radiation or surgical treatment. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings

    Treatment: MRF in conjunction with IVIM MRI without contrast

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Development of Magnetic Resonance Fingerprinting for Characterization of Brain Tumors After Radiotherapy
Plain-language title
Brain scan method to tell radiation damage from returning brain tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06101069, who can take part
Record updated
20 October 2026